Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 617-620

  Meazza, Cristina ^a   Casanova, Michela ^a   Luksch, Roberto ^a   Podda, Marta ^a   Favini, Francesca ^a   Cefalo, Graziella ^a   Massimino, Maura ^a   Ferrari, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bone sarcomas; Chemotherapy; Continuous infusion; High dose; Ifosfamide; Pediatric sarcomas; Relapsing sarcomas; Soft tissue sarcomas

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANISETRON; GROWTH FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; ONDANSETRON; VINCRISTINE; ALKYLATING AGENT;

ADD ON THERAPY; ADOLESCENT; AMBULATORY MONITORING; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSURIA; ELECTROLYTE DISTURBANCE; ERYTHROCYTE TRANSFUSION; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEPSIS; SIDE EFFECT; SYNOVIAL SARCOMA; TREATMENT RESPONSE; URINALYSIS; VOMITING; INFANT; INFUSION PUMP; PRESCHOOL CHILD; SARCOMA;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IFOSFAMIDE; INFANT; INFUSION PUMPS; MALE; SARCOMA;

EID: 77957090848     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22596     Document Type: Article

References (37)

1. Brock N. Oxazaphosphorine cytostatics: Past-present-future. Seventh Cain Memorial Award Lecture. Cancer Res 1989; 49: 1-7.
2. Furlant M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003; 65: 2-6.
3. Carli M, Passone E, Perilongo G, et al. Ifosfamide in pediatric solid tumors. Oncology 2003; 65: 99-104.
4. Dubourg L, Michoudet C, Cochat P, et al. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001; 12: 1615-1623.
5. Takamoto S, Sakura N, Yashiki M, et al. Inactivation of acrolein by sodium 2-mercaptoethanesulfonate using headspace-solid-phase microextraction gas chromatography and mass spectrometry. J Chromatogr B 2003; 791: 365-369.
6. Takamoto S, Sakura N, Namera A, et al. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosfamide. J Chromatogr B 2004; 806: 59-63.
7. Lind MJ, Ardiet C. Pharmacokinetics of alkylating agents. Cancer Surv 1993; 17: 157-188.
8. De Kraker J, Voute PA. Ifosfamide, mesna and vincristine in pediatric oncology. Cancer Treat Rev 1983; 10: 165-166.
9. Pinkerton CR, Rogers H, James C, et al. A phase II study of ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 1985; 15: 258-262.
10. Cerny T, Castiglione M, Brunner K, et al. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990; 335: 175.
11. Antman KH, Ryan L, Wyllie R, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7: 126-131.
12. Boddy AV, Yule SM, Wyllie R. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995; 5: 785-790.
13. Bisogno G, De Bernardi B, Cordero di Montezemolo L. A randomized comparison of ifosfamide administered as continuous or short infusion in children with soft tissue sarcoma. Med Pediatr Oncol 2001; 37: 181. Abstract O74.
14. Benjamin RS, Legha SS, Patel SR, et al. Single agent ifosfamide studies in sarcomas of soft tissue and bone: The MD Anderson experience. Cancer Chemother Pharmacol 1993; 31: S174.
15. Elias A, Eder J, Shea T, et al. High-dose ifosfamide with mesna uroprotection. A phase I study. J Clin Oncol 1990; 8: 170-178.
16. Cerny T, Leyraz S, Dazzi H, et al. Phase II trials of ifosfamide with mesna in advanced soft tissue sarcoma patients: A definitive dose-response relationship. Proc Am Soc Clin Oncol 1992; 11: 416 (Abstr 1462).
17. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-68.
18. Demetri GD. High-dose ifosfamide in the treatment of sarcomas of soft tissue and bones. Semin Oncol 1996; 23: 22-26.
19. Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pre-treated soft tissue sarcomas. Ann Oncol 1997; 8: 1159-1162.
20. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-2384.
21. Buesa JM, Lopez-Pousa A, Martin J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998; 9: 871-876.
22. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 14: 2676-2684.
23. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317-321.
24. De Pas T, De Braud F, Orlando L, et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible? Ann Oncol 1998; 9: 917-919.
25. Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgastrim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-1443.
26. Radford JA, Margison JM, Swindell R, et al. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. Cancer Chemother Pharmacol 26: 144-146.
27. National Cancer Institute. NCI common toxicity criteria, version 1. Investigator's handbook: A manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: U.S. Department of Health and Human Services, Public; Heath Service, National Institute of Health; 1993.
28. Loeffler TM, Weber FW, Hausamen TH. Ambulatory high-dose five-day continuous infusion ifosfamide combination chemotherapy in advanced solid tumors: A feasibility study. J Cancer Res Clin Oncol 1991; 117: S125-S128.
29. Skubitz KM, Hamdan H, Thompson RC, Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993; 72: 2963-2969.
30. Toma S, Palumbo R, Comandone A, et al. Ambulatory four-day continuous infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony stimulating factor in advanced solid tumors: A phase I study. Ann Oncol 1995; 6: 193-196.
31. Comandone A, Frustaci S, Bearz A, et al. Efficacy and tolerability of an ifosfamide continuous infusion in soft tissue sarcoma patients. Abstract to CTOS, Milan, November 1997.
32. Coriat R, Mir O, Camps S, et al. Ambulatory administration of 5-day infusion ifosfamide + mesna: A pilot study in sarcoma patients. Cancer Chemother Pharmacol 2010; 65: 491-495.
33. De Pas T, De Pas T, Curigliano G, et al. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann Oncol 2002; 13: 161-166.
34. Allen LM, Creaven PJ, Nelson RL. Studies on the human pharmacokinetics of isophosphoramide. Cancer Treat Rep 1976; 60: 451-458.
35. Wagner T, Drings P. Pharmacokinetic and bioavailability of oral ifosfamide. Arzneim Forsch 1986; 36: 878-880.
36. Singer JM, Hartley JM, Brennan C. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: A randomized cross-over study. Br J Cancer 1998; 77: 978-984.
37. Rodriguez V, Bodey GP, Freireich EJ. Reduction of ifosfamide toxicity using dose fractionation. Cancer Res 1976; 36: 2945-2948.